IL108501A - Antibodies and pharmaceutical compositions containing them - Google Patents

Antibodies and pharmaceutical compositions containing them

Info

Publication number
IL108501A
IL108501A IL10850194A IL10850194A IL108501A IL 108501 A IL108501 A IL 108501A IL 10850194 A IL10850194 A IL 10850194A IL 10850194 A IL10850194 A IL 10850194A IL 108501 A IL108501 A IL 108501A
Authority
IL
Israel
Prior art keywords
antibody
bat
cell line
cells
hybridoma cell
Prior art date
Application number
IL10850194A
Other languages
English (en)
Other versions
IL108501A0 (en
Inventor
Britta Hardy
Abraham Novogrodsky
Original Assignee
Mor Research Applic Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mor Research Applic Ltd filed Critical Mor Research Applic Ltd
Priority to IL10850194A priority Critical patent/IL108501A/en
Publication of IL108501A0 publication Critical patent/IL108501A0/xx
Priority to CA002182289A priority patent/CA2182289C/en
Priority to AT95910891T priority patent/ATE171461T1/de
Priority to ES95910891T priority patent/ES2124533T3/es
Priority to PCT/US1995/001137 priority patent/WO1995020605A1/en
Priority to DK95910891T priority patent/DK0742795T3/da
Priority to DE69504955T priority patent/DE69504955T2/de
Priority to US08/380,857 priority patent/US5897862A/en
Priority to FI963004A priority patent/FI963004A7/fi
Priority to SI9530125T priority patent/SI0742795T1/xx
Priority to RU96116984/13A priority patent/RU2155190C2/ru
Priority to AU18686/95A priority patent/AU693526B2/en
Priority to EE9600107A priority patent/EE03285B1/xx
Priority to CN95192406A priority patent/CN1052733C/zh
Priority to JP52021095A priority patent/JP3478398B2/ja
Priority to MD96-0296A priority patent/MD1374G2/ro
Priority to EP95910891A priority patent/EP0742795B1/en
Priority to NO19963168A priority patent/NO317020B1/no
Priority to MX9603080A priority patent/MX9603080A/es
Priority to LT96-115A priority patent/LT4225B/lt
Priority to LVP-96-317A priority patent/LV11624B/en
Publication of IL108501A publication Critical patent/IL108501A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Detergent Compositions (AREA)
IL10850194A 1994-01-31 1994-01-31 Antibodies and pharmaceutical compositions containing them IL108501A (en)

Priority Applications (21)

Application Number Priority Date Filing Date Title
IL10850194A IL108501A (en) 1994-01-31 1994-01-31 Antibodies and pharmaceutical compositions containing them
EP95910891A EP0742795B1 (en) 1994-01-31 1995-01-30 Immuno-stimulatory monoclonal antibodies
RU96116984/13A RU2155190C2 (ru) 1994-01-31 1995-01-30 Иммуностимуляторные моноклональные антитела
EE9600107A EE03285B1 (et) 1994-01-31 1995-01-30 Immuunsust stimuleerivad monoklonaalsed antikehad
ES95910891T ES2124533T3 (es) 1994-01-31 1995-01-30 Anticuerpos monoclonales inmunoestimulantes.
PCT/US1995/001137 WO1995020605A1 (en) 1994-01-31 1995-01-30 Immuno-stimulatory monoclonal antibodies
DK95910891T DK0742795T3 (da) 1994-01-31 1995-01-30 Immunstimulerende monoklonale antistoffer
DE69504955T DE69504955T2 (de) 1994-01-31 1995-01-30 Immunstimulierende monoklonale antikörper
US08/380,857 US5897862A (en) 1994-01-31 1995-01-30 Immuno-stimulatory monoclonal antibodies
FI963004A FI963004A7 (fi) 1994-01-31 1995-01-30 Vasta-aineen muodostumista kiihottavia monoklonaalivasta-aineita
SI9530125T SI0742795T1 (en) 1994-01-31 1995-01-30 Immuno-stimulatory monoclonal antibodies
CA002182289A CA2182289C (en) 1994-01-31 1995-01-30 Immuno-stimulatory monoclonal antibodies
AU18686/95A AU693526B2 (en) 1994-01-31 1995-01-30 Immuno-stimulatory monoclonal antibodies
AT95910891T ATE171461T1 (de) 1994-01-31 1995-01-30 Immunstimulierende monoklonale antikörper
CN95192406A CN1052733C (zh) 1994-01-31 1995-01-30 免疫刺激单克隆抗体
JP52021095A JP3478398B2 (ja) 1994-01-31 1995-01-30 免疫刺激性モノクローナル抗体
MD96-0296A MD1374G2 (ro) 1994-01-31 1995-01-30 Anticorpi monoclonali imunostimulatori, procedeu de obţinere a acestora, linii celulare, metodă de tratare a maladiilor şi compoziţie farmaceutică
MX9603080A MX9603080A (es) 1994-01-31 1996-07-29 Anticuerpos monoclonales inmuno-estimulantes.
NO19963168A NO317020B1 (no) 1994-01-31 1996-07-29 Immunstimulatoriske monoklonale antistoffer
LT96-115A LT4225B (en) 1994-01-31 1996-07-30 Immuno-stimulatory monoclonal antibodies
LVP-96-317A LV11624B (en) 1994-01-31 1996-09-06 Immuno-stimulatory monoclonal antibodies

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IL10850194A IL108501A (en) 1994-01-31 1994-01-31 Antibodies and pharmaceutical compositions containing them

Publications (2)

Publication Number Publication Date
IL108501A0 IL108501A0 (en) 1994-05-30
IL108501A true IL108501A (en) 1998-10-30

Family

ID=11065761

Family Applications (1)

Application Number Title Priority Date Filing Date
IL10850194A IL108501A (en) 1994-01-31 1994-01-31 Antibodies and pharmaceutical compositions containing them

Country Status (20)

Country Link
US (1) US5897862A (ro)
EP (1) EP0742795B1 (ro)
JP (1) JP3478398B2 (ro)
CN (1) CN1052733C (ro)
AT (1) ATE171461T1 (ro)
AU (1) AU693526B2 (ro)
CA (1) CA2182289C (ro)
DE (1) DE69504955T2 (ro)
DK (1) DK0742795T3 (ro)
EE (1) EE03285B1 (ro)
ES (1) ES2124533T3 (ro)
FI (1) FI963004A7 (ro)
IL (1) IL108501A (ro)
LT (1) LT4225B (ro)
LV (1) LV11624B (ro)
MD (1) MD1374G2 (ro)
MX (1) MX9603080A (ro)
NO (1) NO317020B1 (ro)
RU (1) RU2155190C2 (ro)
WO (1) WO1995020605A1 (ro)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2145634C1 (ru) * 1998-03-12 2000-02-20 Булычева Татьяна Ивановна Штамм культивируемых клеток мышиной гибридомы, используемый для получения моноклональных антител к ядрышковому антигену, ассоциированному с клеточной пролиферацией
IL129299A0 (en) * 1999-03-31 2000-02-17 Mor Research Applic Ltd Monoclonal antibodies antigens and diagnosis of malignant diseases
RU2192888C1 (ru) * 2001-02-15 2002-11-20 Эпштейн Олег Ильич Лекарственное средство и способ лечения патологического синдрома
CN1294148C (zh) * 2001-04-11 2007-01-10 中国科学院遗传与发育生物学研究所 环状单链三特异抗体
IL145926A0 (en) 2001-10-15 2002-07-25 Mor Research Applic Ltd Peptide epitopes of mimotopes useful in immunomodulation
IL149820A0 (en) 2002-05-23 2002-11-10 Curetech Ltd Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency
DE60334303D1 (de) 2002-07-03 2010-11-04 Tasuku Honjo Immunpotenzierende zusammensetzungen
DE10311248A1 (de) * 2003-03-14 2004-09-30 Müller-Hermelink, Hans Konrad, Prof. Dr. Humaner monoklonaler Antikörper
HRP20120845T1 (hr) * 2003-07-02 2012-11-30 Innate Pharma Protutijela za pan-kir2dl nk-receptor i njihova uporaba u dijagnostici i lijeäśenju
WO2006021955A2 (en) * 2004-08-23 2006-03-02 Mor Research Applications Ltd. Use of bat monoclonal antibody for immunotherapy
EP3530736A3 (en) 2005-05-09 2019-11-06 ONO Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
KR101704734B1 (ko) 2005-07-01 2017-02-09 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
PT2170959E (pt) 2007-06-18 2014-01-07 Merck Sharp & Dohme Anticorpos para o receptor humano de morte programada pd-1
PT2242773T (pt) * 2008-02-11 2017-09-15 Cure Tech Ltd Anticorpos monoclonais para o tratamento de tumores
MD3972C2 (ro) * 2009-03-11 2010-07-31 Ион МЕРЕУЦЭ Remediu şi metodă de tratament al stărilor precanceroase
US8686119B2 (en) 2011-07-24 2014-04-01 Curetech Ltd. Variants of humanized immunomodulatory monoclonal antibodies
EP3049442A4 (en) 2013-09-26 2017-06-28 Costim Pharmaceuticals Inc. Methods for treating hematologic cancers
US9580504B1 (en) 2013-11-07 2017-02-28 Curetech Ltd. Pidilizumab monoclonal antibody therapy following stem cell transplantation
UA122479C2 (uk) 2014-01-24 2020-11-25 Дана-Фарбер Кенсер Інстітьют, Інк. Виділена молекула антитіла, яка зв’язується з людським білком програмованої смерті-1 (pd-1)
PL3099717T3 (pl) 2014-01-31 2019-10-31 Novartis Ag Cząsteczki przeciwciała dla TIM-3 i ich zastosowanie
EA201691765A1 (ru) 2014-03-14 2016-12-30 Новартис Аг Молекулы антител против lag-3 и их применения
TWI693232B (zh) 2014-06-26 2020-05-11 美商宏觀基因股份有限公司 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法
EP3191126B1 (en) 2014-09-13 2020-05-13 Novartis AG Combination therapies of alk inhibitors
TWI773646B (zh) 2015-06-08 2022-08-11 美商宏觀基因股份有限公司 結合lag-3的分子和其使用方法
US20180340025A1 (en) 2015-07-29 2018-11-29 Novartis Ag Combination therapies comprising antibody molecules to lag-3
PE20231958A1 (es) 2015-07-30 2023-12-06 Macrogenics Inc Moleculas de union a pd-1 y metodos de uso de las mismas
JP6869987B2 (ja) 2015-09-01 2021-05-12 アジェナス インコーポレイテッド 抗ｐｄ−１抗体及びその使用方法
BR112018006237A2 (pt) 2015-09-29 2018-10-09 Celgene Corp proteínas de ligação a pd-1 e métodos de uso das mesmas
PT3370768T (pt) 2015-11-03 2022-04-21 Janssen Biotech Inc Anticorpos que se ligam especificamente ao pd-1 e seus usos
CN108367069B (zh) 2015-12-14 2022-08-23 宏观基因有限公司 对于pd-1和ctla-4具有免疫反应性的双特异性分子及其使用方法
CN108495651A (zh) 2015-12-17 2018-09-04 诺华股份有限公司 抗pd-1的抗体分子及其用途
KR102379464B1 (ko) 2016-06-20 2022-03-29 키맵 리미티드 항-pd-l1 항체
EP3515944A4 (en) 2016-09-19 2020-05-06 Celgene Corporation METHOD FOR TREATING IMMUNE DISEASES USING PD-1 BINDING PROTEINS
EP3515943A4 (en) 2016-09-19 2020-05-06 Celgene Corporation METHODS OF TREATING VITILIGO WITH PD-1 BINDING PROTEINS
CN110300599B (zh) 2016-12-07 2024-07-02 艾吉纳斯公司 抗体和其使用方法
US12398209B2 (en) 2018-01-22 2025-08-26 Janssen Biotech, Inc. Methods of treating cancers with antagonistic anti-PD-1 antibodies
GB202107994D0 (en) 2021-06-04 2021-07-21 Kymab Ltd Treatment of cancer
US20240294651A1 (en) 2023-01-30 2024-09-05 Kymab Limited Antibodies

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5182368A (en) * 1986-06-13 1993-01-26 Ledbetter Jeffrey A Ligands and methods for augmenting B-cell proliferation

Also Published As

Publication number Publication date
MD1374F2 (ro) 1999-12-31
NO963168D0 (no) 1996-07-29
FI963004A0 (fi) 1996-07-29
AU693526B2 (en) 1998-07-02
DE69504955D1 (de) 1998-10-29
JP3478398B2 (ja) 2003-12-15
US5897862A (en) 1999-04-27
EE03285B1 (et) 2000-08-15
LV11624B (en) 1997-06-20
WO1995020605A1 (en) 1995-08-03
CA2182289C (en) 2003-10-21
AU1868695A (en) 1995-08-15
NO963168L (no) 1996-09-27
EP0742795A1 (en) 1996-11-20
LV11624A (en) 1996-12-20
CN1052733C (zh) 2000-05-24
DK0742795T3 (da) 1999-06-14
LT96115A (en) 1997-05-26
CA2182289A1 (en) 1995-08-03
EP0742795B1 (en) 1998-09-23
FI963004L (fi) 1996-09-27
DE69504955T2 (de) 1999-05-27
CN1145077A (zh) 1997-03-12
NO317020B1 (no) 2004-07-26
ATE171461T1 (de) 1998-10-15
LT4225B (en) 1997-10-27
IL108501A0 (en) 1994-05-30
FI963004A7 (fi) 1996-09-27
MX9603080A (es) 1998-01-31
JPH09508390A (ja) 1997-08-26
RU2155190C2 (ru) 2000-08-27
ES2124533T3 (es) 1999-02-01
MD1374G2 (ro) 2000-09-30

Similar Documents

Publication Publication Date Title
US5897862A (en) Immuno-stimulatory monoclonal antibodies
WO1995020605A9 (en) Immuno-stimulatory monoclonal antibodies
MXPA96003080A (en) Monoclonal antibodies immuno-estimulan
US7794710B2 (en) Methods of enhancing T cell responsiveness
ES2579277T3 (es) Utilización combinada de un agente de bloqueo CTLA-4 y una terapia linfotóxica en el tratamiento de tumores
Seon et al. Long-lasting complete inhibition of human solid tumors in SCID mice by targeting endothelial cells of tumor vasculature with antihuman endoglin immunotoxin.
US20210214436A1 (en) Multi-specific binding proteins and improvements thereon
US6852320B2 (en) T cell inhibitory receptor compositions and uses thereof
US6197298B1 (en) Modified binding molecules specific for T lymphocytes and their use as in vivo immune modulators in animals
AU2002219229B2 (en) Means for the diagnosis and therapy of CTCL
KR19990022650A (ko) 사람 ｂ7.1 및/또는 ｂ7.2 영장류화된 형태에 특이적인 원숭이 단일클론성 항체 및 이의 약제학적 조성물
CA2179196A1 (en) Method of preventing or treating disease characterized by neoplastic cells expressing cd40
AU2015300006B2 (en) Therapeutic agent for cancer which comprises combination of IL-18 and molecule-targeting antibody
CN109195988A (zh) 用于增强超抗原介导的癌症免疫疗法效力的方法和组合物
US10344073B2 (en) Cell compositions and methods for cancer therapy
KR20110085038A (ko) 항 ｃｄ137-항체 및 독소 결합물을 이용한 ｃｄ137 양성세포의 제거방법
Hardy et al. A monoclonal antibody against a human B lymphoblastoid cell line induces tumor regression in mice
AU2007336564B2 (en) Pharmaceutical compositions capable of inducing apoptosis in tumour cells, useful for diagnosis and treatment of B-Chronic Lymphocytic Leukaemia
Saha et al. CTLA4 (CD152) modulates the Th subset response and alters the course of experimental Leishmania major infection
US20240293546A1 (en) D2c7 egfr and egfr viii bi-specific chimeric antigen receptor constructs and methods of making and using same
JPH01126558A (ja) 抗体依存性細胞性細胞毒性の測定方法
Wang et al. Targeting solid tumors via T cell receptor complementarity-determining region 3δ in an engineered antibody
Kudo et al. Specific targeting immunotherapy of cancer with bispecific antibodies
Hollingworth The manipulation of cellular immunity by monoclonal antibodies in cancer patients
Mukherjee et al. Therapeutic Efficacy of Muci-Specific Cytotoxic T Lymphocytes and CD137 Co-Stimulation in a Spontaneous Mammary Cancer Model

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
NP Permission for amending the patent specification granted (section 66, patents law 1967)
KB Patent renewed
KB Patent renewed
KB Patent renewed
KB Patent renewed
EXP Patent expired